Medtronic PLC $MDT Shares Purchased by Bessemer Group Inc.

Bessemer Group Inc. grew its stake in shares of Medtronic PLC (NYSE:MDT) by 60.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,075,987 shares of the medical technology company’s stock after acquiring an additional 1,537,958 shares during the quarter. Bessemer Group Inc.’s holdings in Medtronic were worth $391,539,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Lodestone Wealth Management LLC acquired a new position in shares of Medtronic during the fourth quarter valued at about $27,000. Anfield Capital Management LLC increased its holdings in shares of Medtronic by 410.7% during the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 230 shares in the last quarter. Board of the Pension Protection Fund acquired a new position in shares of Medtronic during the fourth quarter valued at about $29,000. GoalVest Advisory LLC acquired a new position in shares of Medtronic during the fourth quarter valued at about $29,000. Finally, Valley Wealth Managers Inc. acquired a new position in shares of Medtronic during the third quarter valued at about $29,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Price Performance

Shares of NYSE:MDT opened at $76.91 on Friday. Medtronic PLC has a twelve month low of $74.40 and a twelve month high of $106.33. The company’s 50 day moving average is $85.15 and its 200 day moving average is $93.76. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. The company has a market cap of $98.74 billion, a PE ratio of 21.42, a price-to-earnings-growth ratio of 1.81 and a beta of 0.62.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. During the same quarter in the prior year, the firm posted $1.38 EPS. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts forecast that Medtronic PLC will post 5.57 EPS for the current year.

Medtronic Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were given a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 3.7%. The ex-dividend date was Friday, March 27th. Medtronic’s dividend payout ratio is currently 79.11%.

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the sale, the executive vice president owned 32,768 shares in the company, valued at approximately $3,201,761.28. This represents a 61.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.26% of the company’s stock.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic hired a new chief operations and supply chain officer, a move that could support execution, manufacturing efficiency, and supply chain reliability. Medtronic hires chief operations and supply chain officer
• Positive Sentiment: Brokerage coverage remains supportive, with Medtronic still carrying a “Moderate Buy” consensus recommendation, which can help reinforce investor confidence in the stock. Medtronic PLC Given Consensus Recommendation of Moderate Buy by Brokerages
• Neutral Sentiment: Medtronic’s valuation has been highlighted after a sharp recent share-price pullback, with analysts noting the company remains profitable and diversified across key medical device segments. Assessing Medtronic Valuation After Recent Share Price Weakness
• Neutral Sentiment: Orchestra BioMed updated the AVIM hypertension trial timeline, reducing target enrollment while keeping statistical power intact under an FDA-aligned plan developed with Medtronic; the update appears procedural for now, but it keeps Medtronic’s collaborative pipeline in focus. Should Medtronic’s AVIM Hypertension Trial Shift Require Action From Medtronic Investors?

Wall Street Analysts Forecast Growth

MDT has been the topic of several recent analyst reports. Robert W. Baird upped their price objective on shares of Medtronic from $92.00 to $93.00 and gave the company a “neutral” rating in a report on Wednesday, April 15th. Daiwa Securities Group cut their price objective on shares of Medtronic from $117.00 to $115.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Barclays upped their price objective on shares of Medtronic from $118.00 to $120.00 and gave the company an “overweight” rating in a report on Wednesday, April 1st. Citigroup cut their price target on shares of Medtronic from $117.00 to $110.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. Finally, Wells Fargo & Company began coverage on shares of Medtronic in a report on Friday, January 30th. They issued an “overweight” rating and a $114.00 price target on the stock. Fifteen research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $107.80.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).